WO2023012319 - ANTIMICROBIAL PEPTIDOMIMETICS
National phase entry:
Publication Number
WO/2023/012319
Publication Date
09.02.2023
International Application No.
PCT/EP2022/072039
International Filing Date
04.08.2022
Title **
[English]
ANTIMICROBIAL PEPTIDOMIMETICS
[French]
PEPTIDOMIMÉTIQUES À ACTIVITÉ ANTIMICROBIENNE
Applicants **
BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
UNIVERSITÄT ZÜRICH
Inventors
OBRECHT, Daniel
LUTHER, Anatol
UPERT, Grégory
DESJONQUERES, Nicolas
BRABET, Emile
ZBINDEN, Peter
JUNG, Françoise
ZERBE, Oliver
MÖHLE, Kerstin
Priority Data
21020401.2
05.08.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2937 | |
| EPO | Filing, Examination, Granting | 14865 | |
| Japan | Filing, Examination, Granting | 2464 | |
| South Korea | Filing, Examination, Granting | 2699 | |
| USA | Filing, Examination, Granting | 9190 |
Total:
32,155
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
(I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.[French]
(I) et des sels pharmaceutiquement acceptables de ceux-ci, tels que décrits dans la description et dans les revendications. L'invention concerne également des utilisations thérapeutiques des peptidomimétiques pour le traitement ou la prévention d'infections bactériennes et de maladies associées à des infections bactériennes et des utilisations non thérapeutiques des peptidomimétiques pour la conservation ou la désinfection de produits alimentaires, de produits cosmétiques, de médicaments ou d'autres matériaux contenant des nutriments. De plus, la présente invention concerne un procédé de synthèse efficace au moyen duquel ces composés peuvent, si souhaité, être réalisés dans un format de bibliothèque parallèle. De plus, les peptidomimétiques selon l'invention ont une activité antimicrobienne améliorée, une hémolyse de globules rouges faible ou nulle et une cytotoxicité réduite.